hotspot -WSS

hotspot

author：focus 2025-10-02 21:06:27 - browse：651

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Travel bans should be based on evidence, not politics or fear

explore

WSS

Former reverend arrested for allegedly killing 8

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Democrats decry new health bill for going easy on private equity

STAT Report: Patient voices and perspectives

In venture capital firm's success, lessons for turning crisis into profit

In venture capital firm's success, lessons for turning crisis into profit

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

New lawsuit accuses health insurer Cigna of denying claims in bulk

Walensky prepares to leave CDC — and Congress — behind

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Heart attack and stroke risk calculators need revising

CDC launches VaccineFinder tool to locate Covid

After affirmative action ruling, medical educators look to 'holistic review'

Democrats decry new health bill for going easy on private equity

Duchenne breakthrough therapy leaves behind pioneering families

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Wikipedia

Ohioans vote in high

CDC launches VaccineFinder tool to locate Covid

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Biden warns of ‘dark winter’ during final presidental debate

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Why patients can’t get everything they want on drug pricing

explore

leisure time

hotspot

hotspot